Le Lézard
Classified in: Health
Subject: SVY

Europe Flow Cytometry Market 2021: Reagents and Instruments Supplier Shares and Sales Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities


NEW YORK, Nov. 17, 2017 /PRNewswire/ -- This unique report provides information not available from any other published source, including test volume forecasts, instrument placements and installed base by manufacturer and model, as well as sales and market shares of leading instrument and reagents suppliers.

Read the full report: https://www.reportlinker.com/p05119693

This 5-country report will help current suppliers and potential market entrants identify and evaluate emerging opportunities in the flow cytometry markets during the next five years. The report explores future marketing and technological trends in five major European countries (France, Germany, Italy, Spain, and the UK); provides market share estimates, test volume forecasts, and instrument placements; compares features of major clinical and research flow cytometers; profiles competitors and emerging market entrants; and suggests specific product and marketing opportunities for flow cytometry instruments and reagents.

Rationale

During the next five years, continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the flow cytometry markets worldwide. New molecular diagnostic and monoclonal antibody tests will facilitate existing procedures and provide basis for sensitive, specific and simple assays. The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories. Further advances in IT will reduce the cost of instrument manufacture, service warranty, and permit development of self-troubleshooting, autocalibration and other advanced features. Presently tedious analyses of chromosomal abnormalities, DNA content, and lymphocyte subsets will become more automated and routine.

Contains 270 pages and 75 tables

Read the full report: https://www.reportlinker.com/p05119693

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 22:03
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas Pharma Inc....

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...



News published on and distributed by: